5 Blue Chip Stocks with Dividends

2. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 83

Dividend Yield (as of March 21): 2.95%

Pfizer Inc. (NYSE:PFE) is a biopharmaceutical firm that offers a range of medical treatments and vaccines. It manufactured the popular BioNTech-Pfizer Covid-19 vaccine used around the world, which garnered $36 billion in sales for the firm in 2021.

Pfizer Inc.’s (NYSE:PFE) oral pill for Covid-19 called Paxlovid has also been approved by The United States Food and Drug Administration (FDA), and 35 generic drug manufacturers around the world have recently agreed to produce cheap versions of this medicine, so it could be made available for use of more than 53% of the global population.

Hedge funds were seen buying up on Pfizer Inc. (NYSE:PFE) in the fourth quarter of 2021, where 83 hedge funds reported holding stakes in the firm. In comparison, 74 hedge funds held stakes in the biopharmaceutical firm in the previous quarter. Coatue Management owned 10.31 million shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, worth almost $609 million and representing a 2.7% slice of the fund’s total holdings, making it the top shareholder of Pfizer Inc. (NYSE:PFE).

In the fourth quarter, Pfizer Inc. (NYSE:PFE) posted an EPS of $1.08, beating consensus estimates by $0.21. Revenue for the quarter was recorded at $23.84 billion, up 104.02% year-on-year but falling below analysts’ forecasts by $362.61 million.

Here is what Saturna Capital, an investment firm, had to say about Pfizer Inc. (NYSE:PFE) in its Q3 2021 investor letter:

“The Fund’s strongest performer during the quarter was pharmaceutical manufacturer Pfizer Inc. (NYSE:PFE). The company submitted trial data to the FDA for use of its COVID-19 vaccine for younger children, and it is widely expected that the FDA will approve it. Health authorities also began recommending booster shots of the Pfizer vaccine for select populations, further increasing demand for vaccinations.”